IRIS Research and Development

Meet Our Team

Ongoing clinical research is leading toward more effective treatments for autoimmune diseases, and Dr. Guillermo Valenzuela is committed to participating in research program using the latest treatment options. We are proud to be able to offer our patients leading-edge treatments through our research program. All studies are conducted following FDA clinical practice guidelines for testing on new treatment options not on the market as well as new uses for old treatment options.

Patient participation in research is completely voluntary and may be discontinued at any time. Eligible patients are never included without full disclosure and voluntary approval. Our experienced dedicated research staff would be happy to discuss with you or any family member any of the ongoing trials in the areas of Gout, Systemic Lupus Erythematosus, Rheumatoid arthritis, and Osteoarthritis. If interested in OUR research studies please request an appointment below.

Current Clinical Trials

  • A randomized, controlled pragmatic phase 3B/4 study of baricitinib in patients with rheumatoid arthritis.
  • A randomized, double-blind, placebo-controlled study of ALPN-101 in systemic lupus erythematosus (SLE).
  • A multicenter randomized double-blind placebo-controlled phase 3 study to evaluate the efficacy and safety of anifrolumab in adult patients with active profilerative lupus nephritis.
  • A randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial to evaluate the efficacy, safety, tolerability and pharmacokinetics of HZN-825 in patients with diffuse cutaneos systemic sclerosis.
  • A multicenter, open-label extension trial to evaluate the efficacy, safety and tolerability of HZN-825 in patients with diffuse cutaneous systemic sclerosis.
  • A randomized placebo-controlled study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus.
  • A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus.
  • A phase 2 randomized, double-blind, placebo-controlled efficacy and safety study of VIB7734 for the treatment of moderate to severely active systemic lupus erythematosus.
  • A phase 3B, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of guselkumab administered subcutaneously in participants with active psoriatic arthritis who had an inadequate response and/or intolerance to one prior anti-tumor necrosis factor a agent.
  • A phase 3, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Oral brepocitinib in adults with dermatomyositis.
  • A phase 4, multicenter, open-label, infusion duration study to assess safety, tolerability and efficacy of pegloticase administered with a shorter infusion duration in subjects with uncontrolled gout receiving methotrexate.
  • A multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the efficacy and safety of daxdilimab in adult participants with active proliferative Lupus Nephritis.
  • A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of cenerimod ni adult subjects with moderate-to severe systemic lupus Erythematosus (SLE) on top of background therapy.
  • A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of nipocalimab in participants with active idiopathic inflammatory myopathies.
  • A phase 2, randomized, placebo-controlled, double-blind, parallel-group, efficacy and safety study of bi 685509 ni adults with early progressive diffuse cutaneous systemic sclerosis.

Request More Information

Scroll to Top

We are recruiting patients for the following conditions

Lupus, Lupus Nephritis, Rheumatoid Arthritis, Pemphigus Vulgaris, Scleroderma, Psoriatic Arthritis, Sjögrens, Dermatomyositis, IGG4, Vasculitis.